Miscellaneous Ocular Agents
The triamcinolone and moxifloxacin injection was intended for use as post-op prophylaxis for ocular inflammation and endophthalmitis to eliminate the use of post-op eye drops.
One in 5 of the infants had sight-threatening eye abnormalities, with optic nerve and retinal abnormalities the most common.
Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.
Dexycu injection was developed to help compliance—especially among elderly patients—and avoid dosing errors associated with conventional treatments that depend on self-administered eye drops multiple times a day.
After adjustment for potential confounders, the risk of cataracts was lower among participants in the highest versus the lowest tertile of dietary vitamin K1 intake (hazard ratio, 0.71).
The researchers found that in the intention-to-treat population, 69 and 20% of those who received teprotumumab and placebo, respectively, had a response at week 24.
Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).
Children with active JIA-associated uveitis who were taking a stable dose of methotrexate were randomly assigned to either adalimumab or placebo for 2 weeks.
The researchers observed an increase in cone-like cells after switching rod to cone-like photoreceptors in situ by inactivation of Nrl or Nr2e3.
The analysis indicated that patients with and without DME in the Lucentis treatment group had improvements in the severity of their retinopathy.
The researchers assessed the cardiovascular and cerebrovascular safety of ranibizumab 0.3mg and 0.5mg vs. sham with and without laser in diabetic macular edema.
The researchers found that early AMD was associated with a small reduction in VSF compared with no AMD in adjusted models in a group of ethnic Chinese but not in groups of ethnic Indians or Malays.
The finished product is still some way off being consumer-ready, but when complete it could restore sight to millions of people with degenerative eye diseases.
Young children should be screened at least once for amblyopia before they turn 5 years old, according to a draft recommendation statement issued by the U.S. Preventive Services Task Force.
Valeant have re-submitted their NDA for latanoprostene bunod ophthalmic solution after receiving a Complete Response Letter from the FDA last summer.
The NDA for Dextenza was resubmitted in January 2017 following a Complete Response Letter that was issued in July 2016 due to concerns with deficiencies in manufacturing processes and controls.
To reduce the risk or slow the progression of of diabetic retinopathy, the guidelines recommend optimizing glycemic control, as well as lowering blood pressure and serum lipids.
Young children are suffering vision-threatening burns from the chemicals inside liquid laundry detergent pods in increasing numbers, according to a research letter published online in JAMA Ophthalmology.
Bone marrow-derived mesenchymal stem cell (BMSC)-derived exosomes promote retinal ganglion cell (RGC) survival, according to a study published online in Stem Cells Translational Medicine.
Ocular has announced that it has resubmitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Dextenza (dexamethasone insert) 0.4mg, to treat ocular pain after ophthalmic surgery.
In a case report published online Jan. 19 in Pediatrics, iatrogenic Cushing's syndrome (CS) is described in a 9-year-old girl who received topical ocular glucocorticoid (GC) treatment for bilateral iridocyclitis.
An experimental drug, AXT107, may one day make treatment simpler for patients with age-related macular degeneration, according to research published in the January 18 issue of Science Translational Medicine.
There are fewer cases of incident diabetic retinopathy among obese patients with type 2 diabetes undergoing bariatric surgery compared with medical treatment, according to a review and meta-analysis published online January 13 in Obesity Reviews.
Genentech announced that the Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of patients with myopic choroidal neovascularization (mCNV). This approval marks Lucentis as the first anti-vascular endothelial growth factor (VEGF) approved to treat mCNV in the United States.
Acucela has announced that the Food and Drug Administration (FDA) has granted orphan drug designation to their candidate, emixustat (emixustat hydrochloride), for the treatment of Stargardt disease.
Preeclampsia is associated with increased risk of maternal retinal disease, especially traction detachments, retinal breaks, and diabetic retinopathy, according to a study published in the January issue of Obstetrics & Gynecology.